You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

~ Buy the ZEGALOGUE (AUTOINJECTOR) (dasiglucagon hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

ZEGALOGUE (AUTOINJECTOR) Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Zegalogue (autoinjector), and what generic alternatives are available?

Zegalogue (autoinjector) is a drug marketed by Zealand Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-three patent family members in twenty-four countries.

The generic ingredient in ZEGALOGUE (AUTOINJECTOR) is dasiglucagon hydrochloride. Two suppliers are listed for this compound. Additional details are available on the dasiglucagon hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Zegalogue (autoinjector)

Zegalogue (autoinjector) will be eligible for patent challenges on March 22, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for ZEGALOGUE (AUTOINJECTOR)
International Patents:33
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
DailyMed Link:ZEGALOGUE (AUTOINJECTOR) at DailyMed
Drug patent expirations by year for ZEGALOGUE (AUTOINJECTOR)

US Patents and Regulatory Information for ZEGALOGUE (AUTOINJECTOR)

ZEGALOGUE (AUTOINJECTOR) is protected by two US patents and one FDA Regulatory Exclusivity.

Patents protecting ZEGALOGUE (AUTOINJECTOR)

Glucagon analogues
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING DIABETIC HYPOGLYCEMIA

FDA Regulatory Exclusivity protecting ZEGALOGUE (AUTOINJECTOR)

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zealand Pharma ZEGALOGUE (AUTOINJECTOR) dasiglucagon hydrochloride SOLUTION;SUBCUTANEOUS 214231-002 Mar 22, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Zealand Pharma ZEGALOGUE (AUTOINJECTOR) dasiglucagon hydrochloride SOLUTION;SUBCUTANEOUS 214231-002 Mar 22, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Zealand Pharma ZEGALOGUE (AUTOINJECTOR) dasiglucagon hydrochloride SOLUTION;SUBCUTANEOUS 214231-002 Mar 22, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZEGALOGUE (AUTOINJECTOR)

See the table below for patents covering ZEGALOGUE (AUTOINJECTOR) around the world.

Country Patent Number Title Estimated Expiration
Philippines 12015500115 GLUCAGON ANALOGUES ⤷  Try a Trial
South Korea 20200080331 글루카곤 유사체 (GLUCAGON ANALOGUES) ⤷  Try a Trial
Eurasian Patent Organization 201590058 АНАЛОГИ ГЛЮКАГОНА ⤷  Try a Trial
European Patent Office 2875043 ANALOGUES DU GLUCAGON (GLUCAGON ANALOGUES) ⤷  Try a Trial
Japan 2019187419 グルカゴン類似体 (GLUCAGON ANALOGS) ⤷  Try a Trial
Australia 2013295035 Glucagon analogues ⤷  Try a Trial
Taiwan 201404785 Glucagon analogues ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.